Literature DB >> 19255503

Urocortin II induces nitric oxide production through cAMP and Ca2+ related pathways in endothelial cells.

Elena Grossini1, Claudio Molinari, David A S G Mary, Francesca Uberti, Flavio Ribichini, Philippe Primo Caimmi, Giovanni Vacca.   

Abstract

BACKGROUND: Urocortin II has previously been shown in anesthetized pigs to increase coronary blood flow through activation of the endothelial nitric oxide synthase (eNOS) pathway and involvement of the subtype 2 of corticotropin releasing factor receptors (CRFR2). However, little information has been available regarding the intracellular signalling through these receptors and leading to the release of nitric oxide (NO). AIM: The present study was therefore planned to determine the mechanism involved in such signalling.
METHODS: In porcine aortic endothelial cells (PAE) the effects of urocortin II on NO production and ERK, Akt, p38 and eNOS phosphorylation were examined in absence or presence of the adenylyl cyclase agonist forskolin and antagonist 2'5' dideoxyadenosine, the Ca2+ ionophore A23187, the Ca2+-calmodulin-kinase inhibitor KN93, the CRFR2 blocker astressin 2B and of the protein kinases specific inhibitors UO126, wortmannin and SB203580.
RESULTS: Urocortin II caused a significant increase of NO production, which was amplified by forskolin and A23187 (P <0.05). All effects of urocortin II were abolished by l-NAME, 2'5' dideoxyadenosine, KN93, astressin 2B and by pre-treatment of cells with UO126, wortmannin and SB203580. Western Blot analysis confirmed the involvement of ERK, Akt and p38 in the eNOS activation.
CONCLUSION: In PAE urocortin II interaction with CRFR2 caused a cAMP-dependent and Ca2+-related phoshorylation of ERK, Akt and p38 leading to eNOS activation. 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255503     DOI: 10.1159/000204097

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  7 in total

1.  Evaluation of Serum Urocortin 2 Levels in Patients with Hypertension.

Authors:  Gamze Aslan; Saide Aytekin
Journal:  High Blood Press Cardiovasc Prev       Date:  2020-01-10

Review 2.  Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implications.

Authors:  M Larauche; C Kiank; Y Tache
Journal:  J Physiol Pharmacol       Date:  2009-12       Impact factor: 3.011

Review 3.  Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors.

Authors:  Cornelia Kiank; Yvette Taché; Muriel Larauche
Journal:  Brain Behav Immun       Date:  2009-08-19       Impact factor: 7.217

4.  Urocortin 2 stimulates nitric oxide production in ventricular myocytes via Akt- and PKA-mediated phosphorylation of eNOS at serine 1177.

Authors:  Stefanie Walther; Florentina Pluteanu; Susanne Renz; Yulia Nikonova; Joshua T Maxwell; Li-Zhen Yang; Kurt Schmidt; Joshua N Edwards; Paulina Wakula; Klaus Groschner; Lars S Maier; Joachim Spiess; Lothar A Blatter; Burkert Pieske; Jens Kockskämper
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-07-11       Impact factor: 4.733

Review 5.  Key role of CRF in the skin stress response system.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Blazej Zbytek; Desmond J Tobin; Theoharis C Theoharides; Jean Rivier
Journal:  Endocr Rev       Date:  2013-08-12       Impact factor: 19.871

6.  Regulation and roles of urocortins in the vascular system.

Authors:  Kazunori Kageyama; Ken Teui; Naoki Tamasawa; Toshihiro Suda
Journal:  Int J Endocrinol       Date:  2012-05-13       Impact factor: 3.257

7.  Clinical perspectives of urocortin and related agents for the treatment of cardiovascular disease.

Authors:  Keiichi Ikeda; Kouki Fujioka; Yoshinobu Manome; Katsuyoshi Tojo
Journal:  Int J Endocrinol       Date:  2012-04-03       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.